Insider Trading Alert - MNR, VRX And SBRA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 16, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $442.00 to $2,999,379.00.

Highlighted Stocks Traded by Insiders:

Monmouth Real Estate Investment (MNR) - FREE Research Report

Umh Properties, Inc., who is Shareholder at Monmouth Real Estate Investment, bought 16,165 shares at $8.97 on June 16, 2015. Following this transaction, the Shareholder owned 2.1 million shares meaning that the stake was boosted by 0.79% with the 16,165-share transaction.

Miller Kevin S., who is Chief Financial Officer at Monmouth Real Estate Investment, bought 56 shares at $8.97 on June 16, 2015. Following this transaction, the Chief Financial Officer owned 24,158 shares meaning that the stake was boosted by 0.23% with the 56-share transaction.

The shares most recently traded at $9.37, up $0.40, or 4.27% since the insider transaction. Historical insider transactions for Monmouth Real Estate Investment go as follows:

  • 4-Week # shares bought: 1,266
  • 12-Week # shares bought: 1,510
  • 24-Week # shares bought: 9,243

The average volume for Monmouth Real Estate Investment has been 177,700 shares per day over the past 30 days. Monmouth Real Estate Investment has a market cap of $552.1 million and is part of the financial sector and real estate industry. Shares are down 15% year-to-date as of the close of trading on Tuesday.

Monmouth Real Estate Investment Corporation (MREIC) is a real estate investment trust. It owns, manages, and leases properties to investment-grade tenants on long-term leases. The firm invests in the public equity and real estate markets of the United States. The stock currently has a dividend yield of 6.44%. The company has a P/E ratio of 40.5. Currently, there is 1 analyst who rates Monmouth Real Estate Investment a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNR - FREE

TheStreet Quant Ratings rates Monmouth Real Estate Investment as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and increase in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and weak operating cash flow. Get the full Monmouth Real Estate Investment Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Rosiello Robert L., who is Executive Vice President at Valeant Pharmaceuticals International, bought 12,900 shares at $232.51 on June 16, 2015. Following this transaction, the Executive Vice President owned 12,900 shares meaning that the stake was boosted by 100% with the 12,900-share transaction.

The shares most recently traded at $231.05, down $1.46, or 0.63% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 8,000
  • 4-Week # shares sold: 23,000
  • 12-Week # shares bought: 8,000
  • 12-Week # shares sold: 23,000
  • 24-Week # shares bought: 8,000
  • 24-Week # shares sold: 23,000

The average volume for Valeant Pharmaceuticals International has been 1.7 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $79.0 billion and is part of the health care sector and drugs industry. Shares are up 59.81% year-to-date as of the close of trading on Tuesday.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company has a P/E ratio of 78.2. Currently, there are 8 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sabra Health Care REIT (SBRA) - FREE Research Report

Ettl Robert A., who is Director at Sabra Health Care REIT, bought 2,000 shares at $25.49 on June 16, 2015. Following this transaction, the Director owned 39,673 shares meaning that the stake was boosted by 5.31% with the 2,000-share transaction.

The shares most recently traded at $25.82, up $0.33, or 1.28% since the insider transaction. Historical insider transactions for Sabra Health Care REIT go as follows:

  • 4-Week # shares bought: 697
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 4,197
  • 12-Week # shares sold: 2,500
  • 24-Week # shares bought: 4,197
  • 24-Week # shares sold: 2,500

The average volume for Sabra Health Care REIT has been 329,200 shares per day over the past 30 days. Sabra Health Care REIT has a market cap of $1.5 billion and is part of the financial sector and real estate industry. Shares are down 16.23% year-to-date as of the close of trading on Tuesday.

Sabra Health Care REIT, Inc. operates as a real estate investment trust in the United States. The company, through its subsidiaries, owns and invests in real estate properties for the healthcare industry. The stock currently has a dividend yield of 6.13%. The company has a P/E ratio of 19.4. Currently, there are 5 analysts who rate Sabra Health Care REIT a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SBRA - FREE

TheStreet Quant Ratings rates Sabra Health Care REIT as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Sabra Health Care REIT Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers